and attended conferences sponsored by TrigoCare International, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Pfizer and Sanofi Aventis
Since the SGLT2-i benefits on HF could not be explained by anti-hyperglycemic action in any of these trials, multiple hypotheses have been raised about the potential mechanisms underlying their cardiovascular favorable effects
Detection and quantitation of Bcr-Abl transcripts using a comprehensive quantitative RT-PCR analysis system for minimal residual disease in CML patients
Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies
This rapid kinetics requires multi-daily administrations (2-3 times per day) to maintain chronic stimulation, typically in synergy with an extended-duration GHRH analog such as CJC-1295 DAC
It needs freezing